A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390
combined with Toripalimab in patients with advanced solid tumors. The main questions it aims
to answer are:
- the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390;
- safety and preliminary in combined therapy. Participants will be treated with WX390
orally and Toripalimab intravenously, and follow the efficacy and safety evaluation
according to the protocol.